1192322-46-5Relevant articles and documents
Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition and kit for inhibiting the growth of cancer containing the same as an active ingredient
-
, (2021/07/20)
The present invention relates to: a disubstituted adamantyl derivative or a pharmaceutically acceptable salt thereof, and an anticancer pharmaceutical composition and a kit containing same as an active ingredient. The disubstituted adamantyl derivative according to the present invention suppresses the growth of cancer cells by targeting mitochondria ETC complex I and damaging the metabolism of cancer cells, and thus can be useful as an anticancer pharmaceutical composition that is a powerful therapeutic agent for cancer dependent on oxidative phosphorylation for producing ATP.
A novel class of highly potent multidrug resistance reversal agents: Disubstituted adamantyl derivatives
Min, Kyung Hoon,Xia, Yan,Kim, Eun Kyung,Jin, Yinglan,Kaur, Navneet,Kim, Eun Seon,Kim, Dae Kyong,Jung, Hwa Young,Choi, Yongseok,Park, Mi-Kyung,Min, Yong Ki,Lee, Kiho,Lee, Kyeong
scheme or table, p. 5376 - 5379 (2010/05/19)
Novel disubstituted adamantyl derivatives were synthesized and evaluated in a P-glycoprotein dependent multidrug resistance cancer cell line. The hit to lead optimization provided potent MDR reversal agents. Some potent adamantyl derivatives were more than 10-fold more potent than verapamil without considerable intrinsic cytotoxicity. The 3-trifluorophenyl derivative 14f did not affect the metabolism of CYP450 3A4, whereas most of MDR revertants had a weak inhibitory effect.
